The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA
Open accessAbstract
Significance: CALAA-01 is a targeted nanoparticle containing siRNA that is a first-in-class experimental therapeutic for cancer. To our knowledge, it is the first targeted, polymer-based nanoparticle-carrying siRNA to be systemically administered to humans. Results from a human phase Ia/Ib clinical trial are presented and correlated to preclinical animal data to provide an initial assessment of how this class of experimental therapeutics is translated from animals to humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524 · cited 1×
“Proc Natl Acad Sci USA 104(14):5715–5721.”
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Self-citationDelivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Davis, M. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900015y · Cited by 977
Self-citationTumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers
Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., & Chilkoti, A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj070 · Cited by 920
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Transferrin receptors in human tissues: their distribution and possible clinical relevance.
Gatter, K. C., Brown, G., Trowbridge, I. S., Woolston, R. E., & Mason, D. Y. (1983) · Journal of Clinical Pathology · doi:10.1136/jcp.36.5.539 · Cited by 531
Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382
Self-citationPolycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane
Zuckerman, J. E., Choi, C. H. J., Han, H., & Davis, M. E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200718109 · Cited by 372
Self-citationRibonucleotide Reductase Inhibitors and Future Drug Design
Shao, J., Zhou, B., Chu, B., & Yen, Y. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906777723949 · Cited by 284
Self-citationPhysicochemical and Biological Characterization of Targeted, Nucleic Acid-Containing Nanoparticles
Bartlett, D. W., & Davis, M. E. (2007) · Bioconjugate Chemistry · doi:10.1021/bc0603539 · Cited by 283
Self-citationMisinterpreting the Therapeutic Effects of Small Interfering RNA Caused by Immune Stimulation
Robbins, M., Judge, A., Ambegia, E., Choi, C., Yaworski, E., Palmer, L., McClintock, K., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.131 · Cited by 220
Lack of interferon response in animals to naked siRNAs
Heidel, J. D., Hu, S., Liu, X. F., Triche, T. J., & Davis, M. E. (2004) · Nature Biotechnology · doi:10.1038/nbt1038 · Cited by 183
Self-citationHeidel, J. D., Liu, J. Y.-C., Yen, Y., Zhou, B., Heale, B. S. E., Rossi, J. J., Bartlett, D. W., & Davis, M. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2218 · Cited by 160
Self-citationEliasof, S. D., Lazarus, D. D., Peters, C. G., Case, R. I., Cole, R. O., Hwang, J., Schluep, T., Chao, J., Lin, J. L., Yen, Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309566110 · Cited by 160
Self-citationYu, R. Z., Baker, B. F., Chappell, A. E., Geary, R. S., Cheung, E., & Levin, A. A. (2002) · Analytical Biochemistry · doi:10.1006/abio.2002.5576 · Cited by 138
Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth
Rahman, M. A., Amin, A. R. M. R., Wang, X., Zuckerman, J. E., Choi, C. H. J., Zhou, B., Wang, D., Nannapaneni, S., Koenig, L., Chen, Z., et al. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.045 · Cited by 88
Self-citationSulakhe, P. V., & Dhalla, N. S. (1970) · PubMed · Cited by 46
Allometric scaling of pegylated liposomal anticancer drugs
Caron, W. P., M.A., H. J. C. I., Dedrick, R. L., Ramanathan, R. K., Davis, W. L., Yu, N. Y., Tonda, M. E., Schellens, J. H. M., Beijnen, J. H., & Zamboni, W. C. (2011) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-011-9213-5 · Cited by 41
Inaba, S., Nagahara, S., Makita, N., Tarumi, Y., Ishimoto, T., Matsuo, S., Kadomatsu, K., & Takei, Y. (2012) · Molecular Therapy · doi:10.1038/mt.2011.221 · Cited by 41
Henry, S. P., Monteith, D., Kornbrust, D. J., & Levin, A. A. (1997) · Nucleosides and Nucleotides · doi:10.1080/07328319708006253 · Cited by 14
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
“, kidney toxicity).(124) As such, these differences and similarities must be considered on a case-by-case basis, however, efforts to correlate results should be implemented as soon as possible so general trends, if any, can be established.”
Background
Metadata
- Authors
- Zuckerman, J. E., Gritli, I., Tolcher, A., Heidel, J. D., Lim, D., Morgan, R., Chmielowski, B., Ribas, A., Davis, M. E., & Yen, Y.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2014-07-21
- Volume
- 111
- Issue
- 31
- Pages
- 11449-11454
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2055631278
- Cited by
- 427
- References
- 22
- FWCI
- 13.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.